News - Specialty Devices

OrthogenRx introduces TriVisc medical device to treat osteoarthritic knee pain

Medical device firm OrthogenRx has introduced TriVisc (sodium hyaluronate) to treat patients with osteoarthritic (OA) knee pain.

Scientists develop tiny elastic robots that can adapt to surroundings

Scientists at EPFL and ETH Zurich have developed smart microrobots that are capable of changing their shape depending on their surroundings.

Abbott gets FDA nod for TactiCath SE catheter to treat atrial fibrillation

Helathcare firm Abbott has secured approval from the US Food and Drug Administration (FDA) for its TactiCath contact force ablation catheter, Sensor Enabled (SE), to treat patients with treat atrial fibrillation (AFib).

First human stem cell-derived product candidate implanted in type 1 diabetes patients in Europe

The Center for Beta Cell Therapy in Diabetes and ViaCyte have announced start of European clinical trial of human stem cell-derived implants in type 1 diabetes patients.

VentureMed starts Swiss enrollment for FLEX vessel preparation system

Interventional vascular solutions provider VentureMed Group has started enrollment in Switzerland in the study named BEnefit of arterial vessel preparation by LONGitudinal micro-incisions (BELONG) before drug eluting balloon angioplasty of the superficial femoral and popliteal arteries.

Research says mechanical stress affects normal bone development

Researchers at Okayama University show how mechanical stress at very early stages of bone development alters expression pattern of the non-collagenous matrix responsible for biological property of the bone.

HighLife closes €32m round B financing

HighLife SAS, a medtech company focused on the development of a unique transcatheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced it had closed a €32 million round of equity financing.

Adamis’ commercial partner launches SYMJEPI in US

Adamis Pharmaceuticals announced that its marketing and commercial partner, Sandoz, a Novartis division, has launched SYMJEPI (epinephrine) 0.3 mg Injection in the US market for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.

Medtronic begins trial of SynchroMed II intrathecal drug delivery system

Medtronic has enrolled first patient in its Embrace targeted drug delivery (TDD) clinical trial designed to assess the efficacy of SynchroMed II intrathecal drug delivery system.